Citigroup Inc. raised its holdings in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT – Free Report) by 29.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 111,116 shares of the company’s stock after purchasing an additional 25,109 shares during the period. Citigroup Inc. owned about 0.32% of RAPT Therapeutics worth $2,039,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Braidwell LP bought a new stake in RAPT Therapeutics during the fourth quarter valued at $19,800,000. Kingdon Capital Management L.L.C. increased its stake in RAPT Therapeutics by 30.3% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 880,000 shares of the company’s stock valued at $17,424,000 after purchasing an additional 204,383 shares during the last quarter. Quantbot Technologies LP bought a new stake in RAPT Therapeutics during the second quarter valued at $107,000. California State Teachers Retirement System increased its stake in RAPT Therapeutics by 3.0% during the first quarter. California State Teachers Retirement System now owns 36,450 shares of the company’s stock valued at $669,000 after purchasing an additional 1,070 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in RAPT Therapeutics by 683.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,083 shares of the company’s stock valued at $93,000 after purchasing an additional 4,434 shares during the last quarter. Institutional investors own 99.09% of the company’s stock.
RAPT Therapeutics Trading Up 5.9 %
Shares of NASDAQ RAPT opened at $20.39 on Thursday. RAPT Therapeutics, Inc. has a twelve month low of $15.59 and a twelve month high of $31.45. The company has a market capitalization of $700.60 million, a price-to-earnings ratio of -7.58 and a beta of 0.40. The firm has a 50-day moving average of $21.02 and a two-hundred day moving average of $20.98.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on RAPT shares. Stifel Nicolaus started coverage on shares of RAPT Therapeutics in a report on Tuesday, August 8th. They set a “buy” rating and a $40.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $41.00 price target on shares of RAPT Therapeutics in a report on Monday, August 14th. Barclays initiated coverage on shares of RAPT Therapeutics in a report on Thursday, June 15th. They set an “overweight” rating and a $35.00 price target for the company. JPMorgan Chase & Co. reduced their price objective on shares of RAPT Therapeutics from $39.00 to $32.00 and set an “overweight” rating for the company in a report on Wednesday, August 16th. Finally, Piper Sandler upped their price objective on shares of RAPT Therapeutics from $28.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, August 14th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, RAPT Therapeutics currently has an average rating of “Buy” and an average price target of $38.60.
Insiders Place Their Bets
In other RAPT Therapeutics news, insider William Ho sold 2,500 shares of the business’s stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $18.92, for a total transaction of $47,300.00. Following the sale, the insider now owns 21,289 shares in the company, valued at approximately $402,787.88. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 5.50% of the company’s stock.
RAPT Therapeutics Profile
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
- Five stocks we like better than RAPT Therapeutics
- What is a Secondary Public Offering? What Investors Need to Know
- These Quality Dividend Kings Grow their Dividends the Fastest
- Where to Find Earnings Call Transcripts
- 3 Growth Stocks to Buy in September
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Underappreciated Stocks with Nowhere to Go But Up
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.